CO20 Predictors of Sustainability of Response with Cenobamate: Post-Hoc Subset Analysis of a Phase 3, Open-Label Study

S. Stern,R. Wechsler,W. Kerr, C. Wade,D.G. Vossler,W.E. Rosenfeld

Value in Health（2023）

引用 0|浏览6

暂无评分

摘要

Cenobamate is an antiseizure medication (ASM) approved in the US and EU for the treatment of focal seizures. We evaluated seizure reduction achieved with adjunctive cenobamate and clinical characteristics associated with maintaining response in a post-hoc analysis from a phase 3, open-label, safety study.

查看译文

关键词

cenobamate,sustainability,post-hoc,open-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要